Patrick Daly

Patrick Daly

Patrick joined Pappas Capital in 2019 as an Executive-in-Residence.  He is a seasoned global executive with a proven track record of entrepreneurship, building winning cultures and growing companies small and large. He has a unique ability to create, shape and implement strategic agendas, and motivate diverse teams to achieve results beyond what was expected. Prior to joining Pappas Capital, Patrick founded Cohera Medical, Inc. and shepherded it through commercialization while successfully raising multiple rounds of financing, including from KKR.  The company was previously named the Pittsburgh Technology Counsel Company of the Year and Patrick was honored as CEO of the Year. He was also a three-time Ernst and Young Entrepreneur of the Year finalist.

Patrick was recently the Chairman of the Advanced Medical Technology Association (AdvaMed) Accel Board, the division within AdvaMed dedicated to the needs of smaller medical technology manufacturers. He enjoyed a successful tenure on the Executive Board of AdvaMed and has nurtured and developed strong relationships with the Fortune 500 Med Tech CEOs. Earlier in his career, Patrick spent over 15 years at Johnson & Johnson (J&J) in a variety of cross-functional and international assignments in the U.S. and Asia Pacific. His work using six-sigma to improve the Key Opinion Leaders experience garnered the J&J Corporate Standards of Leadership Award. He has frequently been invited to speak on entrepreneurship and company development at the MBA programs at Carnegie Mellon and the University of Pittsburgh Heinz School of Business.

Patrick has a passion and commitment to America’s military. Along with his classmates from West Point, he founded The Johnny Mac Soldiers Fund, which has raised over $22 million in college scholarships for Gold Star children.

Education:

United States Military Academy at West Point (BS in Foreign Area Studies)

Karen LeVert

Karen has a long history of further developing early stage technologies from university research labs and launching them into the commercial marketplace. These commercialization efforts led to spin-off companies in optoelectronics, medical devices, and agriculture via Southeast TechInventures, Inc. (STI) and Ag TechInventures, LLC (AgTI) – innovation labs she co-founded. Karen’s business experience encompasses both corporate and entrepreneurial worlds with over twenty-five years of successful leadership experience in executive management, start-ups, and technology commercialization. Karen started her career at a Fortune-500 insurance company holding positions of increasing responsibility from computer programmer, to controller, to general manager of a 500-person Property & Casualty service center. Before founding the innovation labs, her first entrepreneurial venture was launching a franchise bioremediation company that she later sold. Her next entrepreneurial venture was co-founding a Silicon Valley based software company. Along with her professional duties Karen serves as a board member for the North Carolina Biotechnology Center, the Economic Development Partnership of North Carolina, the North Carolina School of Science and Math, the NC IDEA Foundation, and LCBA Life Insurance Company.

Education:
University of Dayton (MBA)
Eastern Michigan University (BBA Information Technology)

Peter Young

Peter is an experienced life science industry consultant and leads the firm’s initiatives in translational medicine. He is the Program Manager for the Wake Forest Technology Development Program and also provides business development and due diligence support to the firm’s venture funds and portfolio companies. Peter joined Pappas Capital in 2012, serving initially as an executive-in-residence and currently as a venture partner.

Peter has forty years of experience in the pharmaceutical and biotech industry, spanning all areas of the business from sales representative to country-level general manager and CEO; and companies ranging from multinationals like Abbott and Glaxo to start-up biotechs. As Vice President and Therapy Area Head at Glaxo Wellcome in the mid-1990s, he led the global introduction of combination HIV therapy that revolutionized HIV treatment and quintupled Glaxo’s global HIV portfolio sales, while keying industry leadership on global treatment access. Peter has since served as CEO of two private start-up enterprises, a viral vector vaccine company that raised over $80 million in NIH HIV and biodefense vaccine grants, and a specialty pharmaceutical company he led to an exit via a strategic transaction.

Peter currently serves on the Oversight Committee for the University of Miami Wallace H. Coulter Center for Translational Research, and is a member of the Long Island Bioscience Hub External Review Board. He is also an Executive-in-residence at Cold Spring Harbor Laboratory and the Stony Brook University Center for Biotechnology, and also serves as a mentor-in-residence at Rutgers University. Peter was a past member of the BIO board, past Chairman of the North Carolina Biosciences Organization (NCBIO), and was a director of Memory Pharmaceuticals from 2004 until its sale to Roche in 2009. He has lived and worked in the US, Greece, the Middle East, Puerto Rico, New Zealand and London.

Education:

Indiana University (BA, History)
IU Kelley School of Business (MBA)

Barry Myers, MD, PhD

Barry joined Pappas Capital in 2004 as an Executive-in-Residence. His experience and background enable him to bring a deep knowledge of medical devices, business and clinical practice to the table.

Barry has been a member of the Duke University faculty for 29 years, currently serving as Director of Innovation in the Duke Clinical Translational Science Institute, and Coulter Program Director where he manages seed funding to help commercialize Duke faculty innovation. He is also professor of Biomedical Engineering, with appointments in Surgery and Business Administration. Barry has considerable experience in both business and academic leadership, having served as Managing Director of the Duke Office of Licensing and Ventures. He is recognized as a world leader in injury research and product safety, with over 100 publications. In addition to his roles at Pappas Ventures and Duke, Barry maintains an active consulting practice, advising clients including the NFL, NASCAR and most major automotive manufacturers and U.S. federal organizations concerned with product safety. Barry previously served as a board observer for Pappas Ventures III portfolio companies Gentis and TYRX.

Education:

University of Toronto (BS in Mechanical Engineering)
Duke University (MD)
Duke University (PhD in Biomedical Engineering)
Duke University (MBA)

Russel Kaufman, MD

Russel is currently President Emeritus of The Wistar Institute and previously served as the Director of The Wistar Cancer Center. Prior to his role at The Wistar Institute, he was the Vice Dean and Associate Vice Chancellor at the Duke University School of Medicine, where he is now professor emeritus. He also serves as a Wistar Professor in the Adjunct Faculty at the University of Pennsylvania. His research career focused on cancer, genetics and blood diseases. He is certified in Internal Medicine and has practiced hematology and medical oncology. Russel has held leadership positions in national academic organizations in Internal Medicine and on committees within the NIH, the National Academy of Sciences, the American Cancer Society, and the American Association of Medical Colleges. He has served on the boards of the CEO Council for Growth in Philadelphia, BioAdvance, Osage Ventures, Militia Hill Ventures, and the University City Science Center.

Russel joined Pappas Capital in 2008 as a member of the Scientific Advisory Board, becoming an Executive-in-Residence in 2015.

Education:

Ohio State University (BS in Biochemistry and Zoology)
Ohio State University (MD)
Duke University (Residency)

Antonio Chow

Antonio joined Pappas Capital in 2015 as a Regional Advisor for Asia. Prior to joining Pappas, he was a Senior Vice President of the Nephoxil® business unit for Panion & BF Biotech in Taiwan. Prior to Panion, Antonio served in several senior level positions in Taiwan and China for multinational pharmaceutical companies including Roche, Glaxo and Glaxo Wellcome, including as Chairman of the Board of Roche’s Research and Development Center in China.

In the early part of his career, Antonio held various positions in the pharmaceutical industry in China, Taiwan and Hong Kong, including nine years as a sales and marketing manager with Merrell Dow and the Dow Chemical Company in Greater China and Asia. Antonio in a registered pharmacist in the US states of New Jersey and Florida, as well as in Hong Kong.

Education:

Rutgers State University (Bachelor in Pharmacy)
Fresno State University (BS in Chemistry)

Bob White

With more than 20 years of senior management experience in the medical technology industry, Bob has a keen eye for groundbreaking medical technologies.

Bob joined Pappas in 2014 as a Senior Advisor and also currently serves as President and COO for Entellus Medical (NASDAQ:ENTL), a medical technology company focused on products for the minimally invasive treatment of chronic and recurrent sinusitis patients. From early 2010 through the end of 2013, he was CEO of TYRX, a Pappas Ventures portfolio company that was sold to Medtronic.

Bob has over 20 years of senior management experience in the medical technology industry through numerous positions of increasing responsibility with Medtronic Inc., Instromedix-LifeWatch, ALARIS Medical Systems, Eli Lilly, and General Electric. Bob served as President of Medtronic Kyphon following the $3.9 billion acquisition of the spinal treatment business. During his time with Medtronic, Bob also served as President of Physio Control, Chief Development Officer responsible for all corporate development activities, and Vice President of U.S. Sales and Global Marketing where he was responsible for commercial operations for the Medtronic Cardiac Rhythm Management business.

Bob began his career with General Electric. In 1989 he joined Eli Lilly and through successive promotional opportunities became the International Marketing Manager for IVAC based in Europe for three years. At ALARIS Medical Systems, a $400 million infusion therapy company, his last role was as Vice President, Corporate Development. Bob then became Founder and CEO of Liquid Borders, a healthcare software development company. At Instromedix-LifeWatch, which specializes in selling non-invasive cardiac monitoring solutions, he served as President and CEO.

Education:

University of Missouri-Rolla (BS in Aerospace Engineering)
Cornell University (MBA)

David Savello, PhD

Dave joined Pappas Capital in 2002 as a member of our Scientific Advisory Board, becoming a Venture Advisor in 2012. He regularly provides clinical development guidance to our portfolio companies – including CoLucid Pharmaceuticals, Milestone Pharmaceuticals and Lumena Pharmaceuticals, for which he was a member of the board of directors prior to its acquisition by Shire in 2014.

Dave was most recently Senior Vice President of Development Operations for Xenoport. Prior to Xenoport, he co-founded NDA Partners, a drug development consulting company. Prior to NDA Partners, he was Chief Scientific Officer for Cardinal Health, and before that, Senior Vice President for Drug Development at Guilford Pharmaceuticals. He held senior level positions in drug development and regulatory affairs at Glaxo and Glaxo Wellcome, including Vice President for North American Regulatory Affairs. Prior to Glaxo, Dave held positions with Warner Lambert Corporation, Boehringer Ingelheim and Riker Laboratories. Dave served on the North Carolina State University School of Physical and Mathematical Science Foundation Board, and the University of Maryland School of Pharmacy Advisory Committee. He previously served as a director for Panacos Pharmaceuticals, a Pappas Ventures I portfolio company.

Education:

Massachusetts College of Pharmacy (BS)
University of Maryland School of Pharmacy (MS and PhD in Pharmaceutics)

Ernie Mario, PhD

Knowledge and experience are key drivers of success for life sciences companies. Ernie’s wealth of knowledge from his long career in the pharma industry is an essential sounding board for our investment team.

Ernie’s career began in 1966 as a pharmaceutical researcher at Strasenburgh Laboratories in Rochester, NY. He later held various management positions within SmithKline and Squibb Corp., overseeing operations, quality control, and manufacturing. He was elected to the Squibb Board in 1984. He joined Glaxo plc in 1986, and subsequently served as Chief Executive and Deputy Chairman, during which time he oversaw the launch of five major brands that grew the company’s sales and profits by nearly 15 percent annually, as Glaxo became the second largest global pharmaceutical company. In 1993, Ernie joined Alza Corporation as CEO, where he ultimately consummated with Johnson & Johnson what was then one of the largest mergers in pharmaceutical history. In 2001, Ernie founded Apothogen, a company involved in early-stage pharmaceutical development, which subsequently merged with IntraBiotics. He went on to serve as Chairman and CEO of Reliant Pharmaceuticals, which was acquired by GlaxoSmithKline. In 2007, Ernie joined Soleno Therapeutics (formerly Capnia) as Chairman and CEO, and continues to serve as Chairman. He previously served as a director for Pappas portfolio company Balance Therapeutics and as Chairman for Pappas portfolio company Chimerix (NASDAQ: CMRX). Ernie holds an honorary doctorate from the University of Rhode Island and from Rutgers University, where the School of Pharmacy bears his name. He served as a Duke University trustee for 18 years and in 2009 received the University Medal for Distinguished Meritorious Service. In 2007, he was awarded the Remington Medal, the highest honor in the field of Pharmacy in the United States.

Ernie Joined Pappas Capital in 2002 as a member of our Scientific Advisory Board, becoming a Venture Partner in 2011.

Education:

Rutgers University (BS in Pharmacy)
University of Rhode Island (MS in Physical Sciences)
University of Rhode Island (PhD in Physical Sciences)

Franz Humer, PhD

Franz joined Pappas Capital in December 2013 as a Venture Partner and Senior Advisor, reuniting with Art Pappas and Ernie Mario, who all served together in the early 1990s as senior executives and board members for Glaxo Holdings.

In March 2014, Franz retired as Chairman of Roche Holding Ltd., capping a transformative 15-year tenure as Chairman and/or Chief Executive Officer. He became the CEO for Roche Group in 1998, previously serving as Chief Operating Officer and Head of Pharmaceuticals (F. Hoffmann-La Roche Ltd). Franz began his career in the pharmaceutical industry in 1973, joining Schering Plough Corporation as assistant to the vice president of Europe, Africa, Middle East operations and general manager of Ecuador, UK and Portugal. After leaving Schering Plough, he held various managerial positions (including director) at Glaxo Holdings plc, where he was responsible for research, business development, manufacturing, commercial strategy, and all operations outside the United States. Franz joined the Board of Diageo plc, the world’s leading spirits company, in 2005, and served as Chairman of the Board of Directors from 2008 through 2016. He is an Independent Director of Allogene Therapeutics (San Francisco), Chairman of PCI Pharma Services, Chairman of the Advisory Board of LetterOne Holdings, Independent Director of Walter Frey Holding, and Healthcare Advisor to Temasek Holdings (Singapore).

Franz also serves as Chairman of the board of directors for the International Centre for Missing and Exploited Children, and the Humer Foundation. In 2000, he received the Oliver R. Grace Award for distinguished service in advancing cancer research. Franz holds a Doctor of Law from the University of Innsbruck and an MBA from INSEAD. He also holds an honorary doctorate from the University of Basel and from the School of Pharmacy, University of London.

Education:

University of Innsbruck (PhD in Law)
INSEAD (MBA)
Faculty of Science from the University of Basel (Honorary Doctorate)
School of Pharmacy, University of London (Honorary Doctorate)